Pálmai, N.; Széplaki, N.-Á.; Molnár, B.; Smits, H.; Krejci, R.; Kiss, I.
Non-Compromised Efficacy of the First Commercial Ready-to-Use Genotype 2d Porcine Circovirus Type 2 and Mycoplasma hyopneumoniae Vaccine. Viruses 2025, 17, 554.
https://doi.org/10.3390/v17040554
AMA Style
Pálmai N, Széplaki N-Á, Molnár B, Smits H, Krejci R, Kiss I.
Non-Compromised Efficacy of the First Commercial Ready-to-Use Genotype 2d Porcine Circovirus Type 2 and Mycoplasma hyopneumoniae Vaccine. Viruses. 2025; 17(4):554.
https://doi.org/10.3390/v17040554
Chicago/Turabian Style
Pálmai, Nimród, Nikoletta-Ágnes Széplaki, Bálint Molnár, Han Smits, Roman Krejci, and István Kiss.
2025. "Non-Compromised Efficacy of the First Commercial Ready-to-Use Genotype 2d Porcine Circovirus Type 2 and Mycoplasma hyopneumoniae Vaccine" Viruses 17, no. 4: 554.
https://doi.org/10.3390/v17040554
APA Style
Pálmai, N., Széplaki, N.-Á., Molnár, B., Smits, H., Krejci, R., & Kiss, I.
(2025). Non-Compromised Efficacy of the First Commercial Ready-to-Use Genotype 2d Porcine Circovirus Type 2 and Mycoplasma hyopneumoniae Vaccine. Viruses, 17(4), 554.
https://doi.org/10.3390/v17040554